Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Global state: Response ‐ proxy outcome ‐ mental state: 1. General ‐ average score (Brief Psychiatric Rating Scale by over 24 weeks · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: specific ‐ doctors' assessment of adverse effects… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Quality of life QLS · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with placebo (very low certainty).
Global state: Not improved or worsened ‐ medium term Dichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Not improved or worsened ‐ medium termDichotomised… compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia
ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia
ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).
1 finding from 1 review
Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia
It is very uncertain whether RISPERIDONE changes mental state: no clinically significant response in psychotic… compared with PLACEBO (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE may leads to lower leaving the study early ‐ short term (up to 12 weeks) ‐ any reason compared with PLACEBO (low certainty).
1 finding from 1 review
Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia
It is very uncertain whether RISPERIDONE changes global state: 2. no significant clinical improvement ‐ CGI, short… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia
RISPERIDONE may leads to higher adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term… compared with PLACEBO (low certainty).
1 finding from 1 review
Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia
RISPERIDONE + CLOZAPINE showed no clear difference in mental state: no clinically significant response in psychotic… compared with PLACEBO + CLOZAPINE (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia
RISPERIDONE + CLOZAPINE showed no clear difference in global state: no significant clinical improvement ‐ CGI short term compared with PLACEBO + CLOZAPINE (low certainty).
1 finding from 1 review